Concepts (96)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 8 | 2021 | 968 | 0.710 |
Why?
|
| Pancreatectomy | 6 | 2025 | 140 | 0.670 |
Why?
|
| Liver Neoplasms | 8 | 2021 | 1350 | 0.640 |
Why?
|
| Melanoma | 2 | 2015 | 898 | 0.520 |
Why?
|
| Safety-net Providers | 4 | 2021 | 64 | 0.510 |
Why?
|
| Pancreatic Neoplasms | 5 | 2022 | 709 | 0.490 |
Why?
|
| Postoperative Complications | 6 | 2025 | 3074 | 0.440 |
Why?
|
| Pancreaticoduodenectomy | 4 | 2025 | 105 | 0.440 |
Why?
|
| Sarcoma | 1 | 2016 | 206 | 0.420 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2022 | 165 | 0.420 |
Why?
|
| Disease Management | 1 | 2016 | 544 | 0.380 |
Why?
|
| Drainage | 3 | 2019 | 252 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 380 | 0.340 |
Why?
|
| Hepatectomy | 2 | 2021 | 119 | 0.320 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 1238 | 0.280 |
Why?
|
| Immunotherapy | 1 | 2013 | 742 | 0.280 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 880 | 0.270 |
Why?
|
| Quality of Life | 4 | 2025 | 2029 | 0.250 |
Why?
|
| Pancreatitis, Chronic | 1 | 2025 | 70 | 0.220 |
Why?
|
| Intraoperative Care | 1 | 2025 | 122 | 0.220 |
Why?
|
| Fluid Therapy | 1 | 2025 | 143 | 0.210 |
Why?
|
| Breast Neoplasms | 1 | 2016 | 2586 | 0.210 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 303 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 881 | 0.160 |
Why?
|
| Portal Vein | 1 | 2020 | 86 | 0.160 |
Why?
|
| Pancreatic Cyst | 1 | 2019 | 26 | 0.150 |
Why?
|
| Prognosis | 5 | 2023 | 4799 | 0.150 |
Why?
|
| Venous Thrombosis | 1 | 2020 | 168 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2020 | 490 | 0.140 |
Why?
|
| Retrospective Studies | 12 | 2025 | 17065 | 0.140 |
Why?
|
| Middle Aged | 13 | 2025 | 27801 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 109 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2018 | 1206 | 0.130 |
Why?
|
| Postoperative Care | 1 | 2019 | 307 | 0.130 |
Why?
|
| Hepatitis C | 1 | 2020 | 382 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 5148 | 0.130 |
Why?
|
| Humans | 22 | 2025 | 127095 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2017 | 1234 | 0.120 |
Why?
|
| Nutritional Support | 1 | 2017 | 66 | 0.120 |
Why?
|
| Metabolic Diseases | 1 | 2017 | 132 | 0.120 |
Why?
|
| Survival Rate | 4 | 2021 | 2111 | 0.120 |
Why?
|
| Lymph Nodes | 1 | 2017 | 374 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 629 | 0.110 |
Why?
|
| Liver Transplantation | 2 | 2020 | 1104 | 0.110 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 661 | 0.110 |
Why?
|
| Mass Screening | 1 | 2020 | 802 | 0.110 |
Why?
|
| Disease-Free Survival | 3 | 2023 | 900 | 0.110 |
Why?
|
| Liver Cirrhosis | 1 | 2020 | 875 | 0.100 |
Why?
|
| Female | 13 | 2025 | 68483 | 0.100 |
Why?
|
| Male | 14 | 2025 | 62658 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 754 | 0.100 |
Why?
|
| Aged | 8 | 2025 | 20431 | 0.090 |
Why?
|
| Propensity Score | 2 | 2025 | 250 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1291 | 0.090 |
Why?
|
| Biopsy | 1 | 2015 | 1237 | 0.090 |
Why?
|
| United States | 6 | 2020 | 11386 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2017 | 973 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2018 | 384 | 0.060 |
Why?
|
| Nutritional Status | 2 | 2019 | 298 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2020 | 1194 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2019 | 6242 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2019 | 12567 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1537 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 1309 | 0.040 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2020 | 24 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2020 | 76 | 0.040 |
Why?
|
| Length of Stay | 1 | 2025 | 1378 | 0.040 |
Why?
|
| Amylases | 1 | 2019 | 19 | 0.040 |
Why?
|
| Vulnerable Populations | 1 | 2020 | 143 | 0.040 |
Why?
|
| Health Services Needs and Demand | 1 | 2020 | 167 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2018 | 4972 | 0.040 |
Why?
|
| Minority Groups | 1 | 2020 | 256 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 154 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 204 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 14 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 267 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2017 | 167 | 0.030 |
Why?
|
| Lymphatic Metastasis | 1 | 2017 | 425 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 220 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 211 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2017 | 637 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 1 | 2017 | 385 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 150 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2017 | 1498 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2017 | 1369 | 0.030 |
Why?
|
| Liver | 1 | 2020 | 1742 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2023 | 3933 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2020 | 1178 | 0.020 |
Why?
|
| Animals | 1 | 2013 | 33154 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3259 | 0.020 |
Why?
|
| Adult | 2 | 2025 | 30435 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1758 | 0.020 |
Why?
|
| Time Factors | 1 | 2019 | 6142 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 3588 | 0.020 |
Why?
|
| Biomarkers | 1 | 2017 | 3233 | 0.020 |
Why?
|
| Risk Factors | 1 | 2019 | 10610 | 0.010 |
Why?
|